Cutaneous Squamous Cell Carcinoma (cSCC) Market Report 2026

Cutaneous Squamous Cell Carcinoma (cSCC) Market Overview

• Cutaneous Squamous Cell Carcinoma (cSCC) market size has reached to $7.87 billion in 2025 • Expected to grow to $10.35 billion in 2030 at a compound annual growth rate (CAGR) of 5.6% • Growth Driver: Growing Awareness And Advances In Skin Cancer Care Drive Market Growth • Market Trend: Advancements In PD-L1 Inhibitors And Dual-Action Therapies Enhance Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Cutaneous Squamous Cell Carcinoma (cSCC) Market?

Cutaneous squamous cell carcinoma (cSCC) is a type of skin cancer that develops in the squamous cells of the skin's outer layer. It typically occurs in sun-exposed areas and can range from localized lesions to more aggressive forms that may spread to other parts of the body. The main treatments of cutaneous squamous cell carcinoma (cSCC) are surgical treatment and non-surgical treatment. Surgical treatments involve the removal of cancerous cells through methods like excision or Mohs surgery, ensuring the complete elimination of the tumor while minimizing damage to healthy tissue. The various diagnoses include computed tomography (CT), magnetic resonance imaging (MRI), and biopsy and are used by various applications such as hospitals, cancer institutes, ambulatory surgical centers, and others.

What Is The Cutaneous Squamous Cell Carcinoma (cSCC) Market Growth Forecast?

The cutaneous squamous cell carcinoma (cscc) market size is expected to see strong growth in the next few years. It will grow to $10.35 billion in 2030 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to advancements in skin cancer diagnostics, rising adoption of outpatient procedures, growth of dermatologic oncology centers, improved access to early detection, development of targeted therapies. Major trends in the forecast period include rising adoption of mohs micrographic surgery, increased use of non-surgical therapies, growth of early skin cancer screening, expansion of outpatient cancer treatment, focus on minimally invasive procedures.

Global Cutaneous Squamous Cell Carcinoma (cSCC) Market Segmentation

1) By Treatment: Surgical Treatment, Non-Surgical Treatment 2) By Diagnosis: Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Biopsy 3) By Application: Hospitals, Cancer Institutes, Ambulatory Surgical Centers, Other Applications Subsegments: 1) By Surgical Treatment: Excisional Surgery, Mohs Micrographic Surgery, Curettage And Electrodessication 2) By Non-Surgical Treatment: Radiation Therapy, Cryotherapy, Photodynamic Therapy, Topical Therapies, Systemic Therapies

What Is The Driver Of The Cutaneous Squamous Cell Carcinoma (cSCC) Market?

The growing awareness about skin cancer is projected to propel the growth of the cutaneous squamous cell carcinoma (cSCC) market going forward. Skin cancer is the abnormal growth of skin cells, often caused by excessive UV exposure, and can range from harmless to life-threatening. The growing awareness about skin cancer is due to increased public health campaigns, improved access to information, and a rising emphasis on early detection and prevention, leading to greater demand for diagnostic and treatment solutions. Cutaneous squamous cell carcinoma (cSCC) is useful for advancing skin cancer care by enabling targeted therapies, improving diagnosis, and enhancing patient outcomes, ultimately supporting better disease management. For instance, in January 2024, according to the American Cancer Society, a US-based non-profit organization dedicated to eliminating cancer, there were 104,930 reported cases of skin cancer in 2023, reflecting a 3.2% increase from the 108,270 cases reported in 2022. Therefore, growing awareness about skin cancer will fuel growth in the cutaneous squamous cell carcinoma (cSCC) industry.

Key Players In The Global Cutaneous Squamous Cell Carcinoma (cSCC) Market

Major companies operating in the cutaneous squamous cell carcinoma (cscc) market are F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, GSK plc, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Incyte Corporation, Shanghai Henlius Biotech Inc., Fortress Biotech Inc., Rakuten Medical Inc., Morphogenesis Inc., Vidac Pharma Inc., Pfizer Inc., AstraZeneca plc, AbbVie Inc., Johnson & Johnson, Bayer AG, LEO Pharma A/S, Sun Pharmaceutical Industries Ltd.

Global Cutaneous Squamous Cell Carcinoma (cSCC) Market Trends and Insights

Major companies operating in the cutaneous squamous cell carcinoma (cSCC) market are focusing on advancements in immuno-oncology therapies, such as PD-L1 inhibitors and targeted therapies, to improve patient outcomes and provide effective solutions for managing advanced skin cancer. PD-L1, or programmed death-ligand 1, is a protein that suppresses the immune response by binding to PD-1 receptors on T-cells, helping cancer cells evade immune detection. For instance, in December 2024, Checkpoint Therapeutics Inc., a US-based biotech company, received the FDA approval for Unloxcyt (cosibelimab-ipdl). The innovation lies in its ability to block PD-L1, enhancing the immune system’s ability to fight cancer while offering a safer and more effective treatment option. Additionally, its dual mechanisms of action provide a promising approach for managing advanced cutaneous squamous cell carcinoma (cSCC). The approval was based on results from the CK-301-101 trial, which demonstrated clinically meaningful objective response rates and durable responses in patients with advanced cSCC.

What Are Latest Mergers And Acquisitions In The Cutaneous Squamous Cell Carcinoma (cSCC) Market?

In March 2025, Sun Pharmaceutical Industries Limited, an India-based pharmaceutical company, acquired Checkpoint Therapeutics, Inc. for approximately USD 355 million. Through this acquisition, Sun Pharma gains access to Checkpoint’s FDA-approved anti-PD-L1 therapy Cosibelimab for advanced cutaneous squamous cell carcinoma, thereby expanding its oncology capabilities while improving its commercial scale and global therapeutic reach. Checkpoint Therapeutics Inc. is a US-based provider of immunotherapy and targeted oncology treatments, known for its expertise in developing next-generation immune checkpoint inhibitors.

Regional Outlook

North America was the largest region in the cutaneous squamous cell carcinoma (CSCC) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Cutaneous Squamous Cell Carcinoma (cSCC) Market?

The cutaneous squamous cell carcinoma (cSCC) market consists of revenues earned by providing radiation therapy, chemotherapy services, immunotherapy and targeted therapy services, diagnostic services, and follow-up and support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The cutaneous squamous cell carcinoma (CsCC) market also includes sales of topical treatments such as 5-fluorouracil, imiquimod, monoclonal antibodies, and vaccines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cutaneous Squamous Cell Carcinoma (cSCC) Market Report 2026?

The cutaneous squamous cell carcinoma (cscc) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cutaneous squamous cell carcinoma (cscc) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.